Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CCR2 | P41597 | 6/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13722316 | 0.98 | MAOA (0.41) | MAOAMAOBCA1CA2CA9 | |
| SCHEMBL13722380 | 0.92 | MAOA (0.43) | MAOAMAOBCA1CA2CA9 | |
| SCHEMBL13630756 | 0.84 | PRMT6 (0.41) | SPHK2SPHK1USP2HPGDHSD17B10 | |
| SCHEMBL3244251 | 0.80 | HPGD (0.54) | CA1CA2CA9USP2HPGD | |
| SCHEMBL611010 | 0.80 | HTR6 (0.42) | MAOASPHK2SPHK1USP2HPGD | |
| SCHEMBL21234184 | 0.78 | HPGD (0.51) | CA1CA2CA9USP2HPGD | |
| SCHEMBL4437880 | 0.78 | CA1 (0.41) | CA1CA2CCR2CYP19A1LMNA | |
| SCHEMBL18202515 | 0.77 | SPHK2 (0.38) | SPHK2SPHK1USP2HPGDHSD17B10 | |
| SCHEMBL10235940 | 0.77 | XIAP (0.40) | SPHK2SPHK1USP2HPGDHSD17B10 | |
| SCHEMBL612175 | 0.76 | ALDH1A1 (0.39) | SPHK2SPHK1QRFPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2699554-B1 | SUBSTITUTED 4-ARYL-N-PHENYL-1,3,5-TRIAZIN-2-AMINES | BAYER IP GMBH (DE) | 2016-11-02 | — | — | EP | disclosed |
| EP-2755956-B1 | 2,4-DISUBSTITUTED 5-FLUORO-PYRIMIDINES AS SELECTIVE CDK9 INHIBTORS | BAYER IP GMBH (DE) | 2016-05-18 | — | — | EP | disclosed |
| US-9108926-B2 | Disubstituted 5-fluoro-pyrimidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-08-18 | — | — | US | disclosed |
| US-8916557-B2 | Substituted 4-Aryl-N-phenyl-1,3,5-triazin-2-amines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-12-23 | — | — | US | disclosed |
| US-20140228387-A1 | DISUBSTITUTED 5-FLUORO-PYRIMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-14 | — | — | US | disclosed |
| EP-2755956-A1 | DISUBSTITUTED 5-FLUORO-PYRIMIDINES | Bayer Intellectual Property GmbH (DE) | 2014-07-23 | — | — | EP | disclosed |
| EP-2699554-A1 | SUBSTITUTED 4-ARYL-N-PHENYL-1,3,5-TRIAZIN-2-AMINES | Bayer Intellectual Property GmbH (DE) | 2014-02-26 | — | — | EP | disclosed |
| US-20140045852-A1 | SUBSTITUTED 4-ARYL-N-PHENYL-1,3,5-TRIAZIN-2-AMINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-02-13 | — | — | US | disclosed |
| WO-2013037896-A1 | DISUBSTITUTED 5-FLUORO-PYRIMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-21 | — | — | WO | disclosed |
| WO-2012143399-A1 | SUBSTITUTED 4-ARYL-N-PHENYL-1,3,5-TRIAZIN-2-AMINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045852-A1 | SUBSTITUTED 4-ARYL-N-PHENYL-1,3,5-TRIAZIN-2-AMINES | PAH, NAT1, H1-5 | MAOA 49/4885MAOB 19/4885CA1 4869/4885 |
| US-20140228387-A1 | DISUBSTITUTED 5-FLUORO-PYRIMIDINES | DPYD, DHFR, TYMP | MAOA 663/4885MAOB 177/4885CA1 4862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.